Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue
Product sales	$ 947,219	$ 184,179
Laboratory services	129,420	35,241
Collaboration revenue	0	252,780
Total revenue	1,076,639	472,200
Operating expenses
Cost of products sold	345,967	115,389
Cost of services	315,709	95,430
Research and development	1,953,429	1,108,602
General and administrative	1,538,046	659,392
Sales and marketing	1,399,435	1,024,029
Total operating expenses	5,552,586	3,002,842
Operating loss	(4,475,947)	(2,530,642)
Other income (expense)
Interest and other income	173	35
Interest expense	(41,734)	(96,397)
Foreign currency transaction gains	11,328	0
Change in fair value of derivative financial instruments	0	31,831
Total other income (expense)	(30,233)	(64,531)
Net loss	(4,506,180)	(2,595,173)
Preferred stock dividends	0	(171,741)
Net loss available to common stockholders	$ (4,506,180)	$ (2,766,914)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.36)	$ (5.61)
Weighted average shares outstanding - basic and diluted (in shares)	12,568,941	493,463
Net loss	$ (4,506,180)	$ (2,595,173)
Other comprehensive loss - foreign currency translation	(1,112)	0
Comprehensive loss	$ (4,507,292)	$ (2,595,173)